search
Back to results

Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome

Primary Purpose

Idiopathic Nephrotic Syndrome

Status
Unknown status
Phase
Phase 4
Locations
Greece
Study Type
Interventional
Intervention
7-valent pneumococcal conjugate vaccine
Sponsored by
National and Kapodistrian University of Athens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Idiopathic Nephrotic Syndrome

Eligibility Criteria

2 Years - 20 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or Female
  • Between 2-20 years of age

Exclusion Criteria:

  • serious allergic reaction to previous vaccination
  • history of invasive pneumococcal disease
  • vaccination with pneumococcal conjugate vaccine
  • vaccination with pneumococcal polysaccharide vaccine
  • administration of intravenous immunoglobulin or other blood products during the last 3 months

Sites / Locations

  • 1st Department of Pediatrics, Division of Infectious Diseases 'Aghia Sophia' Children's Hospital, Athens University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

patients

controls

Arm Description

Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A

Outcomes

Primary Outcome Measures

Pneumococcal serotype-specific antibodies and B memory cells

Secondary Outcome Measures

Incidence of relapses of idiopathic nephrotic syndrome

Full Information

First Posted
April 29, 2011
Last Updated
April 29, 2011
Sponsor
National and Kapodistrian University of Athens
search

1. Study Identification

Unique Protocol Identification Number
NCT01346007
Brief Title
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
Official Title
Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Unknown status
Study Start Date
January 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
National and Kapodistrian University of Athens

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether 7-valent pneumococcal conjugate vaccine safely induces immune responses and immunological memory in children with idiopathic nephrotic syndrome in remission.
Detailed Description
Idiopathic nephrotic syndrome (INS) is the most frequent glomerular disease in children under 16 years old with incidence rate 2-7/100,000 patients/year depending on ethnicity. Those patients are susceptible to invasive pneumococcal disease (IPD) including peritonitis, pneumonia with or without pleural effusion and meningitis. Due to increased mortality and risk of relapses associated with IPD, it has been recommended that children with INS should be immunized with pneumococcal conjugate vaccine [1]. However, concerns on vaccine safety and impaired immunogenicity due to INS pathogenesis and immunosuppressive treatment are a hurdle for universal implementation of existing guidelines. To thoroughly evaluate safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children with INS in remission, we will investigate a possible association of vaccination with increased risk for recurrences of INS. We will also study immunogenicity and kinetics of immune response in INS patients and healthy subjects and the effect of different types of treatment on primary immune response and antibody persistence at 12-14 months following vaccination with PCV7.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Idiopathic Nephrotic Syndrome

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
patients
Arm Type
Active Comparator
Arm Description
Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
Arm Title
controls
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
7-valent pneumococcal conjugate vaccine
Other Intervention Name(s)
Prevenar; Wyeth Vaccines
Intervention Description
A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
Primary Outcome Measure Information:
Title
Pneumococcal serotype-specific antibodies and B memory cells
Time Frame
Within the first 30 days after vaccination
Secondary Outcome Measure Information:
Title
Incidence of relapses of idiopathic nephrotic syndrome
Time Frame
Within 12 months after vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or Female Between 2-20 years of age Exclusion Criteria: serious allergic reaction to previous vaccination history of invasive pneumococcal disease vaccination with pneumococcal conjugate vaccine vaccination with pneumococcal polysaccharide vaccine administration of intravenous immunoglobulin or other blood products during the last 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Theodoridou, Dr
Organizational Affiliation
1st Department of Pediatrics, Division of Infectious Diseases 'Aghia Sophia' Children's Hospital, Athens University School of Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Vana Spoulou, Dr
Organizational Affiliation
1st Department of Pediatrics, Division of Infectious Diseases 'Aghia Sophia' Children's Hospital, Athens University School of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Christina Liakou, MD
Organizational Affiliation
1st Department of Pediatrics, Division of Infectious Diseases 'Aghia Sophia' Children's Hospital, Athens University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
1st Department of Pediatrics, Division of Infectious Diseases 'Aghia Sophia' Children's Hospital, Athens University School of Medicine
City
Goudi
State/Province
Athens
ZIP/Postal Code
11527
Country
Greece

12. IPD Sharing Statement

Learn more about this trial

Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome

We'll reach out to this number within 24 hrs